Report: Triple Progress Analysis: Lymphoma, PK Inhibitors & Antibodies TOC

1 Executive Summary

2 Methodology

3 Table of Contents

3.1 List of Boxes
3.2 List of Figures
3.3 List of Tables

4 Lymphoma Therapeutics

4.1 Introduction
- 4.1.1 Disease Definition
- 4.1.2 Etiology & Pathophysiology
- 4.1.3 Epidemiology
4.2 Current Treatment Strategies
- 4.2.1 Hodgkin's Disease
- 4.2.2 Non-Hodgkin's Lymphoma
- 4.2.3 Prognosis
4.3 Progress in Current Treatment Strategies
- 4.3.1 HODGKIN
- 4.3.2 NON-HODGKIN
4.4 Key Therapeutic Strategies
- 4.4.1 Antibodies & Immunostimulation
- 4.4.2 Small molecules: Apoptosis inducers & Kinase inhibitors
4.5 Current Drug Development: The Late Stage Pipeline
- 4.5.1 Progress Analysis: aldesleukin
- 4.5.2 Progress Analysis: Arsenic trioxide
- 4.5.3 Progress Analysis: BiovaxID
- 4.5.4 Progress Analysis: bortezomib
- 4.5.5 Progress Analysis: LymphoCide
- 4.5.6 Progress Analysis: FavId
- 4.5.7 Progress Analysis: MyVax
- 4.5.8 Progress Analysis: Nelarabine
- 4.5.9 Progress Analysis: Genasense
- 4.5.10 Progress Analysis: Marqibo
- 4.5.11 Progress Analysis: Pixantrone
- 4.5.12 Progress Analysis: CCI-779
- 4.5.13 Progress Analysis: HuMax-CD4
- 4.5.14 Progress Analysis: Bortezomib
4.6 Current Drug Development: The Early Stage Pipeline
- 4.6.1 Progress analysis: bevacizumab
- 4.6.2 Progress Analysis: CMC-544
- 4.6.3 Progress Analysis: galiximab
- 4.6.4 Progress Analysis: LY317615
- 4.6.5 Progress Analysis: SGN-40
- 4.6.6 Progress Analysis: Hu1D10
- 4.6.7 Progress Analysis: SGN-30

5 Therapeutic Antibodies

5.1 Key Developmental Strategies
5.2 Treating Colorectal Cancer
- 5.2.1 Avastin
- 5.2.2 Erbitux
5.3 Treating Lymphomas
- 5.3.1 Rituxan
- 5.3.2 Bexxar
- 5.3.3 Zevalin
5.4 Treating Leukemias
- 5.4.1 ALL
- 5.4.2 CLL
- 5.4.3 AML
- 5.4.4 CML
- 5.4.5 Campath
- 5.4.6 Mylotarg
5.5 Treating Lung cancer
- 5.5.1 Cotara
5.6 Antibody Deals on the Rise
- 5.6.1 Antibody Deals in Phase III
- 5.6.2 Antibody Deals in Phase II
5.7 New Approaches in Antibody Delivery and Design - The Next Generation
- 5.7.1 How to Make Them Smaller and Different?
- 5.7.2 Biomaterials in Sustained Delivery Applications
- 5.7.3 Gene delivery - the Future?
5.8 Current Analysis of Antibodies in Clinical Development
- 5.8.1 Prostate Cancer Therapeutics
- 5.8.2 Breast Cancer Therapeutics
- 5.8.3 Colorectal Cancer Therapeutics
- 5.8.4 Melanoma Therapeutics
- 5.8.5 Hematological Cancers Therapeutics
5.9 Antibodies in Phase III Clinical Development
- 5.9.1 Progress Analysis: IGN 101
- 5.9.2 Progress Analysis: MDX 010
- 5.9.3 Progress Analysis: ONYVAX 105
- 5.9.4 Progress Analysis: Ovarex
- 5.9.5 Progress Analysis: Panitumumab
- 5.9.6 Progress Analysis: RENCAREX
- 5.9.7 Progress Analysis: Nimotuzumab
- 5.9.8 Progress Analysis: TransMID
- 5.9.9 Progress Analysis: Lintuzumab
- 5.9.10 Progress Analysis: Zanolimumab
5.10 Antibodies in Phase II Clinical Development
- 5.10.1 Progress Analysis: ABT-510
- 5.10.2 Progress Analysis: BB 10901
- 5.10.3 Progress Analysis: CP 675206
- 5.10.4 Progress Analysis: CNTO-328
- 5.10.5 Progress Analysis: Ecromeximab
- 5.10.6 Progress Analysis: EMD 273063
- 5.10.7 Progress Analysis: WX-G250RIT
- 5.10.8 Progress Analysis: HGS-ETR1
- 5.10.9 Progress Analysis: HuMax-CD20
- 5.10.10 Progress Analysis: HuMax-EGFr
- 5.10.11 Progress Analysis: Galiximab
- 5.10.12 Progress Analysis: PROXINIUM
- 5.10.13 Progress Analysis: RAV12
- 5.10.14 Progress Analysis: SGN-15
- 5.10.15 Progress Analysis: SGN-30
- 5.10.16 Progression Analysis: VEGF-Trap
- 5.10.17 Progress Analysis: MEDI 522
- 5.10.18 Progress Analysis: Volociximab
5.11 Cancer Therapeutic Antibodies in Clinical Development

6 Protein Kinase Inhibitors

6.1 Rationale for Development of Kinase Inhibitors in Oncology
6.2 Protein Kinase Targets - A Growing Family
6.3 Challenges in Protein Kinase Drug Discovery
- 6.3.1 Enabling Structure-Based Drug Design is the Key
- 6.3.2 Specific Kinase Inhibitors without Kinase Profiling?
6.4 Drugs according to Target
- 6.4.1 Cyclin-dependent Kinase Target Inhibitors
- 6.4.2 Aurora Kinase Target Inhibitors
- 6.4.3 Cell Cycle Checkpoint Target Controls Inhibitors
- 6.4.4 Tyrosine Kinase Receptor Inhibitors
- 6.4.5 Other Serine/Threonine Kinase Target Inhibitors
6.5 Dual or Multiple Kinase Inhibitor Analysis
- 6.5.1 Presentation of Drugs Targeting A to F Kinases
- 6.5.2 Presentation of Drugs Targeting G to T Kinases
6.6 Targets According to Indication
- 6.6.1 Breast Cancer
- 6.6.2 Prostate Cancer: What Cannot be Found in the 'Groins'?
- 6.6.3 Lung Cancer: A Need for Improved Survival Rates
- 6.6.4 Colorectal Cancer: EGFR & VEGFR are Strong Targets but There are Others
- 6.6.5 Leukemia: Show Me the Power of PKI
- 6.6.6 Melanoma
- 6.6.7 Lymphoma: We Are In
6.7 Growing Competition in the Field
6.8 Big Pharma Outlook: The Race is On
- 6.8.1 Novartis Deals - Digs Deeper into Cell Cycle Inhibitors
- 6.8.2 AstraZeneca - Wheeling and Dealing
- 6.8.3 Pfizer's Long Look at OSI Pharmaceuticals
- 6.8.4 GlaxoSmithKline Gains Momentum
6.9 Strategic Deals Creating Competitive Edge
- 6.9.1 Mergers
- 6.9.2 Astex - the PKI Switchboard
- 6.9.3 Big Pharma's Darling
6.10 Current Protein Kinase Inhibitors in Therapy
- 6.10.1 Mechanism, Target and Developmental History
- 6.10.2 Approvals: Indications & Markets
6.11 Protein Kinase Inhibitors in Drug Development - A Progress Analysis
- 6.11.1 Progress Analysis - Breast Cancer
- 6.11.2 Progress Analysis - Prostate Cancer
- 6.11.3 Progress Analysis - Lung Cancer
- 6.11.4 Progress Analysis - Colorectal Cancer
- 6.11.5 Progress Analysis - Leukemia
- 6.11.6 Progress Analysis - Melanoma
- 6.11.7 Progress Analysis - Lymphoma

7 Appendix I: Selected Company R&D Summarizes in Lymphoma

7.1.1 Accentia BioPharmaceuticals
7.1.2 Biogen Idec
7.1.3 Cell Therapeutics
7.1.4 Chiron Corporation
7.1.5 Cephalon
7.1.6 Eli Lilly
7.1.7 Favrille
7.1.8 Genentech
7.1.9 Genitope Corporation
7.1.10 Genmab
7.1.11 Genta
7.1.12 GlaxoSmithKline
7.1.13 Immunomedics
7.1.14 Inex Pharmaceuticals
7.1.15 Millennium Pharmaceuticals
7.1.16 Protein Design Labs
7.1.17 Roche
7.1.18 Sanofi-Aventis
7.1.19 Seattle Genetics
7.1.20 Wyeth

Company index

Drug index

List of Boxes

Box 1 Possible Complications of Treatment
Box 2 Updated REAL/WHO Classification for B-Cell Neoplasms
Box 3 Subclassification of stage
Box 4 Updated REAL/WHO Classification for B-Cell Neoplasms
Box 5 Updated REAL/WHO Classification for T-Cell and Putative NK-Cell Neoplasms
Box 6 Staging subclassification system
Box 7 Study details
Box 8: The Principal Terms of Deal between AstraZeneca and Cambridge Antibody Technology
Box 9: Marrion's Drug Delivery Technology
Box 10: Quick Facts - IGN 101
Box 11: Quick Facts - MDX 010
Box 12: Quick Facts - ONYVAX 105
Box 13: Quick Facts - Ovarex
Box 14: Quick Facts - Panitumumab
Box 15: Quick Facts - RENCARNEX
Box 16: Quick Facts - Nimotuzumab
Box 17: Quick Facts - RENCARNEX
Box 18: Quick Facts - Lintuzumab
Box 19: Quick Facts - Zanolimumab
Box 20: Quick Facts - ABT-510
Box 21: Quick Facts - BB 10901
Box 22: Quick Facts - CP-675206
Box 23: Quick Facts - CNTO-328
Box 24: Quick Facts - Ecromeximab
Box 25: Quick Facts - EMD-273063
Box 26: Quick Facts - WX-G250RIT
Box 27: Quick Facts - HGS-ETR1
Box 28: Quick Facts - HuMax-CD20
Box 29: Quick Facts - HuMax-EGFr
Box 30: Quick Facts - Galiximab
Box 31: Quick Facts - PROXINIUM
Box 32: Quick Facts - RAV12
Box 33: Quick Facts -SGN-15
Box 34: Quick Facts -SGN-30
Box 35: Quick Facts - VEGF-Trap
Box 36: Quick Facts - MEDI 522
Box 37: Quick Facts - Volociximab
Box 38: The Power of Ambit's Kinase Profiling
Box 39: Summary Terms of the Exelixis Transaction

List of Figures

Figure 1 Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways
Figure 2 Top 10 PKI Drug Developing Companies
Figure 3 Clinical Trial Distribution in Breast Cancer for PKI Drugs
Figure 4 Clinical Trial Distribution in Prostate Cancer for PKI Drugs
Figure 5 Clinical Trial Distribution in Lung Cancer for PKI Drugs
Figure 6 Clinical Trial Distribution in Colorectal Cancer for PKI Drugs
Figure 7 Clinical Trial Distribution in Leukemia for PKI Drugs
Figure 8 Clinical Trial Distribution in Melanoma for PKI Drugs
Figure 9 Clinical Trial Distribution in Lymphoma for PKI Drugs

List of Tables

Table 1 Drugs used in the treatment of lymphoma
Table 2 Summary of Strategies Enhancing Antibody Function
Table 3 Cancer immunotherapy strategies
Table 4 Protein Kinase Targets in Clinical Trials for Lymphoma
Table 5 Recent published studies Aldesleukin
Table 6 Recent published studies Arsenic trioxide
Table 7 Recent published studies BiovaxID
Table 8 Recent Published Studies Bortezomib
Table 9 Recent published studies epratuzumab
Table 10 Recent published studies FavId
Table 11 Recent published studies MyVax
Table 12 Recent published studies Nelarabine
Table 13 Recent published studies Genasense
Table 14 Recent published studies Pixantrone
Table 15 Recent published studies temsirolimus
Table 16 Recent published studies Zanolimumab
Table 17 Recent published studies Flavopiridol
Table 18 Recent published studies bevacizumab
Table 19 Recent published studies CMC-544
Table 20 Recent published studies galiximab
Table 21 Recent published studies LY317615
Table 22 Recent published studies SGN-40
Table 23 Recent published studies Apolizumab
Table 24 Recent published studies SGN-30
Table 25: Summary of Strategies Enhancing Antibody Function
Table 26: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies
Table 27: Drug Delivery Companies with Cancer Focus
Table 28: FDA Approved Polymer-based Drug Delivery Systems for Cancer
Table 29: Antibody Therapeutics in Prostate Cancer
Table 30: Antibody Therapeutics in Breast Cancer
Table 31: Antibody Therapeutics in Colorectal Cancer
Table 32: Antibody Therapeutics in Melanoma
Table 33: Antibody Therapeutics in Hematological Cancer
Table 34: MDX-010's Collaborative History and Landscape
Table 35: Overview of Targets in Commercial Development
Table 36: Cyclin-dependent Kinase Targets in Development
Table 37: Aurora Kinase Targets in Development
Table 38: Cell Cycle Checkpoint Targets in Development
Table 39: Epidermal Growth Factor Receptor Targets in Development
Table 40: FMS-like tyrosine kinases and their Synonyms
Table 41: Fms-related Tyrosine Kinase Targets in Development
Table 42: Platelet-derived Growth Factor Receptor Targets in Development
Table 43: Kinase Insert Domain Targets in Development
Table 44: Drugs in Development Targeting the PI3K/Akt/mTOR pathway
Table 45: Drugs in Development Targeting the Ras-Raf-MEK-ERK (ERK) pathway
Table 46: Serine/Threonine Kinase Inhibitors in Development
Table 47: Protein Kinase Targets in Clinical Trials for Breast Cancer
Table 48: Protein Kinase Targets in Clinical Trials for Prostate Cancer
Table 49: Protein Kinase Targets in Clinical Trials for Lung Cancer
Table 50: Protein Kinase Targets in Clinical Trials for Colorectal Cancer
Table 51: Protein Kinase Targets in Clinical Trials for Leukemia
Table 52: Protein Kinase Targets in Clinical Trials for Melanoma
Table 53: Protein Kinase Targets in Clinical Trials for Lymphoma
Table 54: Drugs in Therapy - Mechanism & Targets
Table 55: Current and Developmental History of PKI Drugs in Therapy
Table 56: Approvals: Indications & Markets
Table 57: Top 10 Drugs in Terms of Number of Clinical Trials
Table 58: List of Cancer Indications Targeted by Protein Kinase Inhibitors
Table 59: PKI Drugs in Development for Breast Cancer
Table 60: PKI Drugs in Development for Prostate Cancer
Table 61: PKI Drugs in Development for Lung Cancer
Table 62: PKI Drugs in Development for Colorectal Cancer
Table 63: PKI Drugs in Development for Leukemia
Table 64: PKI Drugs in Development for Melanoma
Table 65: PKI Drugs in Development for Lymphoma
Table 66 Accentia BioPharmaceuticals anticancer pipeline
Table 67 Biogen anticancer pipeline
Table 68 Cell Therapeutics anticancer pipeline
Table 69 Chiron Corporation anticancer pipeline
Table 70 Cephalon anticancer pipeline
Table 71 Eli Lilly anticancer pipeline
Table 72 Favrille anticancer pipeline
Table 73 Genentech anticancer pipeline
Table 74Genitope anticancer pipeline
Table 75 Genmab anticancer pipeline
Table 76 Genta anticancer pipeline
Table 77 GlaxoSmithKline anticancer pipeline
Table 78 Immunomedics anticancer pipeline
Table 79 Inex Pharmaceuticals anticancer pipeline
Table 80 Millennium Pharmaceuticals anticancer pipeline
Table 81 Protein Design Labs anticancer pipeline
Table 82 Roche anticancer pipeline
Table 83 Sanofi-Aventis anticancer pipeline
Table 84 Seattle Genetics anticancer pipeline
Table 85 Wyeth anticancer pipeline